Biogen (BIIB) News Today $156.00 +0.57 (+0.37%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Biogen (NASDAQ:BIIB) Given New $207.00 Price Target at MizuhoMizuho decreased their price objective on Biogen from $251.00 to $207.00 and set an "outperform" rating on the stock in a research note on Thursday.November 21 at 8:31 AM | marketbeat.comPrimecap Management Co. CA Sells 23,215 Shares of Biogen Inc. (NASDAQ:BIIB)Primecap Management Co. CA decreased its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 0.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,315,079 shares of the biotechnology company's stock afteNovember 21 at 7:03 AM | marketbeat.comBiogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation UpsideNovember 20 at 1:32 PM | benzinga.comBiogen Q3 Earnings TranscriptNovember 20 at 7:06 AM | marketbeat.comBiogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right NowNovember 20 at 4:15 AM | msn.comUCB, Biogen present results from PHOENYCS GO studyNovember 19 at 6:02 AM | tipranks.comThrivent Financial for Lutherans Reduces Stake in Biogen Inc. (NASDAQ:BIIB)Thrivent Financial for Lutherans lowered its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 2.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 188,653 shares of the biotechnology company's stock after selling 3,854 shares during thNovember 19 at 5:02 AM | marketbeat.comEmpowered Funds LLC Has $3.67 Million Holdings in Biogen Inc. (NASDAQ:BIIB)Empowered Funds LLC increased its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 455.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,908 shares of the biotechnology company's stock after buying an adNovember 19 at 4:34 AM | marketbeat.comUCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Treating Moderate-to-Severe Systemic Lupus ErythematosusNovember 19 at 3:02 AM | quiverquant.comUCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO StudyNovember 19 at 2:16 AM | markets.businessinsider.comRobert W. Baird Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock PriceNovember 19 at 1:33 AM | americanbankingnews.comDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityNovember 19 at 1:00 AM | globenewswire.comNeedham downgrades Biogen (BIIB) to a HoldNovember 18 at 6:43 PM | markets.businessinsider.comNeedham downgrades Biogen to Hold on lack of share catalystsNovember 18 at 6:43 PM | markets.businessinsider.comNeedham downgrades Biogen on slow growth of Alzheimer's drugNovember 18 at 6:43 PM | msn.comNeedham Downgrades Biogen (BIIB)November 18 at 6:43 PM | msn.comBiogen cut to hold by Needham on lack of catalysts, slow Leqembi salesNovember 18 at 6:43 PM | msn.comBiogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026November 18 at 2:01 PM | benzinga.comBiogen (NASDAQ:BIIB) Sets New 12-Month Low - Should You Sell?Biogen (NASDAQ:BIIB) Hits New 12-Month Low - Should You Sell?November 18 at 9:43 AM | marketbeat.comBiogen (NASDAQ:BIIB) Downgraded to "Hold" Rating by Needham & Company LLCNeedham & Company LLC downgraded Biogen to a "hold" rating and set a $270.00 target price for the company. in a research report on Monday.November 18 at 7:29 AM | marketbeat.comSamsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™November 18 at 7:00 AM | globenewswire.comIs Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?November 18 at 5:36 AM | uk.finance.yahoo.comIs Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?November 18 at 5:05 AM | insidermonkey.comBiogen Inc. (NASDAQ:BIIB) Shares Sold by KBC Group NVKBC Group NV cut its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 20.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,229 shares of the biotechnology company's stNovember 18 at 4:20 AM | marketbeat.comCitigroup Begins Coverage on Biogen (NASDAQ:BIIB)November 18 at 2:09 AM | americanbankingnews.comBiogen (NASDAQ:BIIB) Coverage Initiated at Wolfe ResearchNovember 18 at 2:09 AM | americanbankingnews.comSeizert Capital Partners LLC Has $2.13 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)Seizert Capital Partners LLC raised its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 45.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,004 shares of the biotechnology company's sNovember 17, 2024 | marketbeat.comCautious Optimism for Biogen: Hold Rating Amidst European Approval DevelopmentsNovember 16, 2024 | markets.businessinsider.comBiogen Inc. (NASDAQ:BIIB) Shares Bought by Mizuho Securities USA LLCMizuho Securities USA LLC increased its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 2,715.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 316,000 shares of the biotechnology company's stock after acquiring an additional 304,778 shares durNovember 16, 2024 | marketbeat.comImpax Asset Management Group plc Buys 11,185 Shares of Biogen Inc. (NASDAQ:BIIB)Impax Asset Management Group plc lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 40.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,810 shares of the biotechnNovember 16, 2024 | marketbeat.comING Groep NV Lowers Position in Biogen Inc. (NASDAQ:BIIB)ING Groep NV reduced its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 20.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,650 shares of the biotechnology company's stock after selling 4,945 sNovember 16, 2024 | marketbeat.comLos Angeles Capital Management LLC Buys Shares of 4,282 Biogen Inc. (NASDAQ:BIIB)Los Angeles Capital Management LLC purchased a new position in Biogen Inc. (NASDAQ:BIIB - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,282 shares of the biotechnology company's stock, valued at approxiNovember 16, 2024 | marketbeat.comWolfe Research Initiates Coverage of Biogen (BIIB) with Peer Perform RecommendationNovember 15, 2024 | msn.comPositive EMA Reversal Boosts Biogen’s Leqembi Prospects Despite ChallengesNovember 15, 2024 | markets.businessinsider.comCitigroup Initiates Coverage of Biogen (BIIB) with Neutral RecommendationNovember 15, 2024 | msn.comBiogen (BIIB) Gets a Buy from TD CowenNovember 15, 2024 | markets.businessinsider.comBiogen (NASDAQ:BIIB) Now Covered by Analysts at Wolfe ResearchWolfe Research began coverage on Biogen in a research note on Friday. They issued a "peer perform" rating for the company.November 15, 2024 | marketbeat.comCornercap Investment Counsel Inc. Invests $1.37 Million in Biogen Inc. (NASDAQ:BIIB)Cornercap Investment Counsel Inc. bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,065 shares of the biotechnology company's stock, valuedNovember 15, 2024 | marketbeat.comBiogen (NASDAQ:BIIB) Stock Price Expected to Rise, Robert W. Baird Analyst SaysRobert W. Baird increased their price target on shares of Biogen from $294.00 to $300.00 and gave the stock an "outperform" rating in a research report on Friday.November 15, 2024 | marketbeat.comCitigroup Upgrades Biogen (NASDAQ:BIIB) to HoldCitigroup raised Biogen to a "hold" rating in a research note on Wednesday.November 15, 2024 | marketbeat.comPrime Capital Investment Advisors LLC Sells 5,201 Shares of Biogen Inc. (NASDAQ:BIIB)Prime Capital Investment Advisors LLC lessened its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 50.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,079 shares of the biotechnology company's stock after selliNovember 15, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Purchases 9,254 Shares of Biogen Inc. (NASDAQ:BIIB)Sumitomo Mitsui Trust Group Inc. increased its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 370,128 shares of the biotechnology company's stockNovember 15, 2024 | marketbeat.comWolfe starts Biogen at Peer Perform, sees limited downside riskNovember 14, 2024 | tipranks.comBiogen up 5% after EMA recommends Leqembi for early Alzheimer’s diseaseNovember 14, 2024 | markets.businessinsider.comEisai and Biogen Receive Positive CHMP Opinion for Lecanemab to Treat Early Alzheimer’s Disease in EuropeNovember 14, 2024 | quiverquant.comEuropean committee takes a second look at Alzheimer's drug and now says it should be approvedA European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drugNovember 14, 2024 | marketbeat.comBiogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drugNovember 14, 2024 | marketwatch.com5 Healthcare Stocks to Buy in a Beaten-Up SectorNovember 14, 2024 | barrons.comEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's DiseaseNovember 14, 2024 | globenewswire.comEU drugs regulator recommends Alzheimer's drug from Eisai-BiogenNovember 14, 2024 | reuters.com Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Related Videos BIIB Media Mentions By Week BIIB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIIB News Sentiment▼0.610.46▲Average Medical News Sentiment BIIB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIIB Articles This Week▼5619▲BIIB Articles Average Week Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Today Pinnacle West Capital News Today Portland General Electric News Today CRISPR Therapeutics News Today Denali Therapeutics News Today American Electric Power News Today Regeneron Pharmaceuticals News Today Alnylam Pharmaceuticals News Today United Therapeutics News Today Incyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIIB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
